Viral Vector Upstream Processing

Bioreactor graphic representing viral vector production

Optimizing the upstream portion of the gene therapy production workflow sets the stage for successful manufacturing by maximizing viral vector titers. Without the benefit of a proven template, however, process development teams must evaluate all aspects of viral vector production including:

To minimize variability and risk across these process inputs, gene therapy manufacturers can collaborate with an experienced technology partner with expertise in all aspects of viral vector production as well as related products and services.

Related Technical Resources

Page 1 of 2

Thaw and Expand Cells and Seeds

Frozen cells from a working or master cell bank are thawed and expanded to increase their numbers in preparation for subsequent processing steps.

Media and Inoculum Prep

Cell culture media are optimized with the appropriate nutrients, supplements, and pH for cell growth and virus production.

Cell Growth and Virus Production

Cells are grown in a bioreactor or other controlled environment under specific conditions to maximize virus production.

Cell Lysis

In AAV production, host cells are lysed by chemical or mechanical means so that the viruses can be released into the media.

DNA Digestion

Unwanted whole cell and plasmid DNA is digested using a nuclease enzyme.


Gene Therapy Manufacturing

Gene Therapy Manufacturing

The rise of gene therapies is driving rapid innovation, but manufacturers face complex challenges bringing new therapies to life

Viral Vector Downstream Processing

Efficient virus purification processes can improve yield, decrease time to patient, and lower manufacturing costs

Viral Vector Formulation and Final Fill

Formulating a commercially viable gene therapy demands a high level of application and regulatory expertise

Viral Vector Characterization and Biosafety Testing

Critical biosafety testing and characterization of viral vector products can help mitigate safety concerns and increase product understanding

Viral Vector Contract Development and Manufacturing

CDMO partnerships play a critical role in advancing clinical pipelines and achieving successful commercialization

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?